![]() ![]() This action includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered to individuals 6 months of age and older, including for an additional dose or doses for certain populations.įDA Authorizes Bivalent Pfizer-BioNTech COVID-19 Vaccine as Booster Dose for Certain Children 6 Months through 4 Years of Age Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. ( agenda)įDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines ET)įDA and the Biomedical Advanced Research and Development Authority (BARDA) are hosting a virtual workshop to provide: 1) a forum for product sponsors to discuss progress and technical challenges in the manufacturing when changing strain composition to currently circulating variants of SARS-CoV-2 and 2) an open forum for collaborative discussions to facilitate advancement of recombinant protein-based COVID-19 vaccines. Recombinant Protein-Based COVID-19 Vaccines Workshop (9:00 a.m. additional doses that may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |